Two and a half years after Guardian Bikes opened a factory in Indiana, it is trying to find components made in the U.S.

New Year's Day will mark the advent of new laws impacting Inland Empire motorists, as well as those statewide, with ...

On Friday, Morgan Stanley (NYSE:MS) maintained its Equalweight rating on Bicycle Therapeutics (NASDAQ:BCYC) with a steady price target of $30.00. The firm's analyst emphasized that the recent ...

Bicycle's immuno-oncology pipeline is headed by BT7480, a tumour-targeted immune cell agonist (TICA) that binds to Nectin-4 on cancer cells and stimulates CD137 on immune cells, driving an immune ...

JMP Securities analyst Reni Benjamin lowered the firm’s price target on Bicycle Therapeutics (BCYC) to $26 from $32 and keeps an Outperform rating on the shares. The firm is pushing back its ...

B. Riley lowered the firm’s price target on Bicycle Therapeutics (BCYC) to $17 from $28 and keeps a Neutral rating on the shares. The stock dropped 35% intraday and now trading near cash after ...

Anti-Israel graffiti and swastikas daubed on bicycles in Jewish neighborhoods of Australian city for over a year; community leaders accuse operator Lime of not tackling problem ...

On Monday, B.Riley updated its assessment of Bicycle Therapeutics (NASDAQ:BCYC) shares, significantly reducing the biopharmaceutical company's price target from $28.00 to $17.00 while maintaining ...

On Monday, H.C. Wainwright adjusted its price target for shares of Bicycle Therapeutics (NASDAQ:BCYC), a biopharmaceutical company, reducing it to $33.00 from the previous $55.00. The stock, currently ...

On Monday, B.Riley updated its assessment of Bicycle Therapeutics (NASDAQ:BCYC) shares, significantly reducing the biopharmaceutical company's price target from $28.00 to $17.00 while maintaining a ...